☆ 4.7 Meeting Abstract

Initial results of a first-in-human, dose escalation study of a cell-based vaccine in HLA A*02+patients (pts) with recurrent, locally advanced or metastatic HPV16+solid tumors: SQZ-PBMC-HPV-101.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Journal

JOURNAL OF CLINICAL ONCOLOGY

Volume 39, Issue 15, Pages -

Publisher

LIPPINCOTT WILLIAMS & WILKINS

DOI: 10.1200/JCO.2021.39.15_suppl.2536

Keywords

Funding

SQZ Biotechnologies

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7

Not enough ratings

Initial results of a first-in-human, dose escalation study of a cell-based vaccine in HLA A*02+patients (pts) with recurrent, locally advanced or metastatic HPV16+solid tumors: SQZ-PBMC-HPV-101.

Journal

JOURNAL OF CLINICAL ONCOLOGY

Publisher

LIPPINCOTT WILLIAMS & WILKINS

Keywords

Categories

Funding

Ask authors/readers for more resources

Protocol

Reagent

Authors

I am an author on this paper

Reviews

Primary Rating

Secondary Ratings

Novelty

Significance

Scientific rigor

Rate this paper

Recommended

Initial results of a first-in-human, dose escalation study of a cell-based vaccine in HLA A*02+patients (pts) with recurrent, locally advanced or metastatic HPV16+solid tumors: SQZ-PBMC-HPV-101.

Journal

JOURNAL OF CLINICAL ONCOLOGY

Publisher

LIPPINCOTT WILLIAMS & WILKINS

Keywords

Categories

Funding

Ask authors/readers for more resources

Protocol

Reagent

Authors

I am an author on this paper

Reviews

Primary Rating

Secondary Ratings

Novelty

Significance

Scientific rigor

Rate this paper

Recommended

Export Citation

Share Paper